WHO and partners have launched the Global Roadmap for Hypertensive Disorders of Pregnancy from 2026 to 2035 and beyond. These disorders complicate an estimated 10-15% of pregnancies, account for about 16% of maternal deaths, and are linked to roughly 42,000 maternal deaths plus more than 500,000 stillbirths and newborn deaths each year. The roadmap joins research, clinical guidance, access to medicines and diagnostics, implementation, advocacy and accountability. Current gaps include basic blood-pressure measurement, urine-protein testing, aspirin, antihypertensives, magnesium sulfate, referral and emergency obstetric care. This is not a successful-drug announcement; impact depends on national budgets, frontline execution and measurable coverage.